Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
Healthcare
$0.69 +2.93%
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
52W Low $0.56High $3.62
Volume 1.71M
Average 1.16M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$26.39M
FY 2025 · Annual
Investing Cash Flow
-$2.03M
FY 2025 · Annual
Financing Cash Flow
-$15,268.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$36.1M
+ D&A$16.3K
+ Stock-Based Comp$1.3M
+ Deferred Tax$0
+ Working Capital$6.3M
+ Other Non-Cash$2.1M
= Operating Cash Flow-$26.4M
- Capex-$33.9K
= Free Cash Flow-$26.4M
Analysis
FY2025 free cash flow is -$26.4M. FCF conversion is 73.1% of net income. Operating cash flow was -$26.4M, with capex of -$33.9K. The largest bridge item is Working Capital at $6.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 8-K | Current report | Jun 26, 2026 |
Does CNTX generate free cash flow?
Context Therapeutics Inc. (CNTX) generated -$26.42M of free cash flow in fiscal 2025.
How much operating cash flow does CNTX produce?
Operating cash flow was -$26.39M, before capital expenditures of $33,948.00.
Continue the stock analysis
Jump to another research area for this company.